

1 **Title:** Seroprevalence of chikungunya and o'nyong-nyong viruses in Senegal, West
2 Africa

3
4 **Authors:** Prince Baffour Tonto^{1,2}, Mouhamad Sy³, Ibrahima Mbaye Ndiaye³, Mariama
5 Toure³, Amy Gaye³, Mariama Aidara³, Amadou Moctar Mbaye³, Abdoulaye Kane Dia^{3,4},
6 Mamadou Alpha Diallo³, Jules Francois Gomis³, Mamadou Samba Yade³, Younous
7 Diedhiou³, Baba Dieye³, Khadim Diongue³, Mame Cheikh Seck³, Aida S. Badiane³,
8 Bobby Brooke Herrera^{1,2*}, Daouda Ndiaye³

9
10 **Affiliations:**

11 1 Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA

12 2 Department of Medicine, Division of Allergy, Immunology, and Infectious Diseases
13 and Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical
14 School, New Brunswick, NJ, USA

15 3 International Research Training Center on Genomics and Health Surveillance
16 (CIGASS), Cheikh Anta Diop University, Dakar, 16477, Senegal

17 4 Laboratoire d'ecologie vectorielle et parasitaire

18
19 ***Corresponding Author:** BBH, bherrera@globalhealth.rutgers.edu

20

21

22

23 **Abstract**

24 **Background**

25 Arthritogenic alphaviruses such as chikungunya (CHIKV) and o'nyong-nyong (ONNV)
26 viruses have shown capacity to cause widespread epidemics, with recurrent and
27 sporadic outbreaks occurring throughout sub-Saharan Africa.

28 **Methods**

29 We analyzed the seroprevalence for CHIKV and ONNV in 470 non-febrile subjects from
30 three regions in Senegal (Sindia, 2018; Thies, 2018; and Kedougou, 2022/2023) using
31 retrospective samples. We assessed the presence of anti-CHIKV IgG and neutralizing
32 titers against CHIKV and ONNV via enzyme-linked immunosorbent assay (ELISA) and
33 microneutralization tests, respectively, and determined risk factors of CHIKV and ONNV
34 exposure by binary logistic regression.

35 **Results**

36 The overall seroprevalence of anti-CHIKV IgG was 24.89% (117/470). Regional
37 seroprevalences were 14.89% (14/94) in Sindia, 28.72% (27/94) in Thies, and 26.95%
38 (76/282) in Kedougou. Among CHIKV IgG-positive samples, 29.91% (35/117) and
39 39.32% (46/117) had neutralizing antibodies against CHIKV and ONNV, respectively. Of
40 the remaining samples, 20.51% (24/117) were equivocal and 10.26% (12/117) were
41 negative. Multivariate analysis showed that residence in Thies significantly increased
42 the likelihood of CHIKV infection (OR, 3.878; 95% CI: 0.783-19.205), whereas prior
43 malaria infection reduced it (aOR, 0.121; 95% CI: 0.049-0.300). Conversely, older age
44 (OR, 7.896; 95% CI: 1.500-41.556) and residence in Kedougou (OR, 3.180; 95% CI:

45 0.824-12.276) were significant risk factors for ONNV infection, with prior malaria
46 infection also linked to higher ONNV susceptibility (aOR, 6.961; 95% CI: 2.456-19.732).

47 **Conclusions**

48 Our study confirms significant exposure to CHIKV and ONNV across Senegal,
49 underscoring the importance of ongoing surveillance and alphavirus testing among the
50 population.

51

52 **Author summary**

53 Arthritogenic alphaviruses, such as chikungunya (CHIKV) and o'nyong-nyong (ONNV)
54 viruses have the potential to cause widespread epidemics, with recurrent and sporadic
55 outbreaks occurring throughout sub-Saharan Africa. This study presents a retrospective
56 evaluation of CHIKV and ONNV seroprevalence among non-febrile subjects from three
57 regions in Senegal: Sindia, Thies, and Kedougou. Our analysis revealed regional
58 variation in alphavirus seroprevalence, with 29.91% of subjects exhibiting neutralizing
59 antibodies against CHIKV and 39.32% against ONNV. We identified that residence in
60 Thies was a risk factor for CHIKV, while residence in Kedougou, a history of malaria,
61 and older age were risk factors for ONNV. These findings suggest significant exposure
62 to CHIKV and ONNV across Senegal, underscoring the importance of ongoing
63 surveillance and alphavirus testing among the population.

64

65

66

67 Introduction

68 Arboviruses transmitted by mosquitoes pose a growing global health threat,
69 significantly impacting morbidity and mortality. Among these, chikungunya (CHIKV) and
70 o'nyong-nyong (ONNV) viruses are notable members of the alphavirus genus,
71 recognized for their substantial effects on human health (1, 2). CHIKV, first isolated in
72 Tanzania in 1952, has caused major outbreaks across Africa, Asia, and the Americas
73 (3-5). Its transmission primarily involves *Aedes* mosquitoes, and its capacity for
74 widespread dissemination was highlighted by the 2004 epidemic that originated in
75 Kenya and rapidly extended to various regions, including the Indian Ocean islands and
76 South and Southeast Asia (1, 5-7). By 2011, CHIKV reached the Western Hemisphere,
77 spreading through the Caribbean and South America by 2014, resulting in hundreds of
78 thousands of infections (8-10).

79 ONNV, identified in Uganda in 1959, has caused significant epidemics primarily
80 in East and West Africa, with major outbreaks recorded in the 1950s and early 1990s
81 (11-13). Transmitted by *Anopheles* mosquitoes, ONNV remains largely confined to the
82 African continent (6). The first major epidemic occurred from 1959 to 1962, affecting
83 over 2 million people across East and West Africa (14, 15). A subsequent outbreak from
84 1996 to 1997 primarily impacted Uganda, Kenya, and Tanzania, with infection rates
85 ranging from 45-68% (14, 16). Despite its geographical confinement, ONNV has been
86 detected in travelers returning from endemic regions (17).

87 Clinically, infections with CHIKV and ONNV are generally self-limiting but can
88 present a spectrum of symptoms including fever, arthralgia, rash, headache, and
89 malaise (18, 19). CHIKV is particularly associated with persistent arthralgia in patients

90 (20). Although ONNV is endemic to Africa, comprehensive data on its morbidity and
91 mortality are limited due to inadequate surveillance. The clinical features of alphavirus
92 infections closely resemble those caused by other pathogens including *Plasmodium*
93 (malaria) or *Salmonella* (typhoid fever) species, which are endemic in many West
94 African countries (21-26). This symptom overlap complicates diagnosis and can lead to
95 underreporting of CHIKV and ONNV, as their symptoms may be misattributed to other
96 febrile illnesses.

97 In West Africa, including Senegal, autochthonous cases of CHIKV have been
98 reported since 1960, with periodic outbreaks continuing up to 2023 (27-31). Despite
99 these occurrences, current data on the seroprevalence of CHIKV and ONNV in Senegal
100 remains limited. This study aims to address this knowledge gap by investigating the
101 seroprevalence of CHIKV and ONNV in Senegal. Given the antigenic similarities
102 between these viruses, our approach focuses on using microneutralization assays to
103 help differentiate between them to provide a more in-depth understanding of their
104 prevalence. By enhancing our knowledge of the epidemiological landscape of CHIKV
105 and ONNV in Senegal, we hope to inform public health strategies and contribute
106 valuable insights into the broader context of arboviral transmission in West Africa.

107

108 **Methods**

109 **Study Population and Ethics Statement**

110 The samples included in our study were originally collected as part of malaria
111 and non-malarial surveillance among residents of Thies, Sindia, and Kedougou,
112 Senegal. Samples from Thies and Sindia were part of the surveillance of non-malarial

113 febrile illnesses, while samples from Kedougou were part of genomic surveillance of
114 malaria. Informed consent was obtained from all subjects and/or their legal guardians
115 for the initial sample collection as well as for its future use. All methods were performed
116 in accordance with the guidelines and regulations set forth by the Declaration of
117 Helsinki. The primary studies under which the samples and data were collected
118 received ethical clearance from the CIGASS Institutional Review Board (IRB) (Protocol
119 numbers: SEN15/46, 19300, and SEN14/49). All excess samples and corresponding
120 data were banked and de-identified prior to the analyses.

121

122 **CHIKV viral like particle (VLP) ELISA**

123 CHIKV VLPs (20 ng per well; Native Antigen) were coated onto Nunc Maxisorp
124 96-well plates (ThermoFisher) overnight, followed by blocking (1X PBST, 1% BSA;
125 ThermoFisher) for 1 hour, then washing (1X PBST three times) and incubation with
126 primary antibodies for 2 hours (serum at 1:400 dilution) at room temperature. The plates
127 were washed three times with 1X PBST and bound sera were reacted with secondary
128 antibodies (anti-human IgG conjugated with horseradish peroxidase [HRP];
129 ThermoFisher), according to the manufacturer's instructions. The plates were washed
130 three more times and allowed to develop with 1-Step TMB ELISA Substrate
131 (ThermoFisher), according to the manufacturer's instructions. The OD at 450 nm was
132 read with a reference wavelength of 650 nm using an ELISA reader (Diasource). We
133 interpreted the ELISA assay as follows: 1) sample absorbance / negative control
134 absorbance ≤ 1.5 , negative; 2) sample absorbance / negative control absorbance > 1.5 ,
135 positive.

136 **Serum Microneutralization Assays**

137 Microneutralization assays were performed to detect neutralizing antibodies
138 against CHIKV and ONNV in samples that were IgG positive for CHIKV VLP. Sera were
139 diluted in a two-fold series from 1:40 to 1:10,240 in PBS in a 96-well plate. For each
140 dilution, contact was performed with 100 plaque forming units (PFU) of CHIKV (BEI
141 Resources: NR-56523) or ONNV (BEI Resources: NR-51661) for one hour at 37°C in a
142 5% CO₂ incubator. The complexes were then added to Vero cells (ATCC) CCL-81, 1.3 x
143 10⁵ cells per well. After 3-4 days of incubation, the cytopathogenic effects were
144 investigated by 0.2% crystal violet (SigmaAldrich) staining. After staining for 2-4 hours,
145 the plates were washed with copious amounts of tap water. For negative controls, at
146 least 3 alphavirus-naïve serum samples were used to incubate with CHIKV or ONNV
147 prior to pipetting onto the Vero cells per plate. For positive controls, 100 PFU of CHIKV
148 or ONNV without any contact with serum were placed on Vero cells in triplicate per
149 plate.

150 The neutralizing titer was defined as the inverse of the highest dilution resulting
151 in an infectious reduction of 50%. A titer lower than 1:40 was considered as negative if
152 cytopathogenic effects were not observed. Samples were considered as positive if the
153 titer was ≥1:40, i.e., positive for ONNV if ONNV titers were at least two-fold higher than
154 CHIKV titers, and CHIKV positive if CHIKV titers were at least four-fold higher than
155 ONNV titers (32). The threshold was lower for ONNV than CHIKV because of the
156 unique one-way cross-reactivity between CHIKV and ONNV, i.e., CHIKV antibodies are
157 more likely to cross-react with ONNV antigens than ONNV antibodies with CHIKV
158 antigens (33). All other results were interpreted as equivocal. 20 Senegalese serum

159 samples that were previously determined to be alphavirus-naïve, were used to validate
160 the assay. Each assay used at least 4 alphavirus-naïve serum samples as negative
161 controls.

162 **Statistical Analysis**

163 Categorical variables are represented as case counts and proportions. To
164 estimate the association between seroprevalence of alphavirus and demographics
165 factors, including age group, gender, city, and malaria status, univariate and multivariate
166 binary logistic regression analyses were performed. The adjusted odd ratios of the
167 independent variables were computed by adjusting for age and gender as confounding
168 variables. Statistical analyses were conducted using IBM SPSS statistics software
169 version 28. The map of Senegal, heatmap, and graph representing rates and
170 percentages of CHIKV and ONNV neutralizing antibodies were generated using R
171 version 4.3.2 and Prism version 10.2.0.

172 **Results**

173 A total of 470 samples collected from non-febrile subjects were included in the
174 study. These samples were collected from three locations in Senegal: Sindia (n=94),
175 Thies (n=94), and Kedougou (n=282) (Table 1). The samples from Sindia and Thies
176 were malaria-negative by rapid diagnostic testing, whereas the samples from Kedougou
177 were from subjects with malaria (Table 1). Participants' ages ranged from 6 months to
178 85 years, with an overall median age of 21 years. The study population was comprised
179 of 44.89% females (n=211) (Table 1).

180

181

182 **Table 1. Baseline characteristics and chikungunya virus (CHIKV) and o'nyong-**
 183 **nyong virus (ONNV) serology**

Characteristic and Serology	Sindia (n=94)	Thies (n=94)	Kedougou (n=282)	Total (N=470)
Demographics				
Year(s) samples collected	2018	2018	2022-2023	
Median age (range)	24 (2-70)	20 (6 months-69)	21 (2-85)	21 (6 months-85)
% Female (number)	41.49 (39)	54.25 (51)	42.91 (121)	44.89 (211)
Malaria status, number (%)				
Positive	0 (0)	0 (0)	282 (100)	282 (60)
Negative	94 (100)	94 (100)	0 (0)	188 (40)
CHIKV VLP IgG, number (%)				
Positive	14 (14.89)	27 (28.72)	76 (26.95)	117 (24.89)
Negative	80 (85.11)	67 (71.28)	206 (73.05)	353 (75.11)
NT50, number/total (%)				
CHIKV	6/14 (42.86)	18/27 (66.67)	11/76 (14.47)	35/117 (29.91)
ONNV	4/14 (28.57)	4/27 (14.81)	38/76 (50)	46/117 (39.32)
Equivocal	4/14 (28.57)	5/27 (18.52)	15/76 (19.74)	24/117 (20.51)
Negative	0 (0)	0 (0)	12/76 (15.79)	12/117 (10.26)

184

185

186

187

188


189

190

191

192 Among the samples tested (n=470) for CHIKV VLP IgG antibodies, 117 tested
193 positive, indicating an overall alphavirus seroprevalence of 24.89% (Table 1).
194 Seroprevalence rates varied by location. Sindia had a rate of 14.89% (14/94), Thies had
195 28.72% (27/94), and Kedougou had 26.95% (76/282). In the serological analysis, a
196 multivariate logistic regression revealed that subjects over 40 years old were more likely
197 to have been exposed to an alphavirus, based on IgG reactivity to CHIKV VLP (OR,
198 2.100; 95% CI: 1.107-3.986) (S1 Table). Additionally, being a resident of Thies (OR,
199 2.384; 95% CI: 1.151-4.939) and Kedougou (OR, 5.591; 95% CI: 3.001-10.418) were
200 associated with increased odds having been exposed to an alphavirus, with the highest
201 risk observed in Kedougou (S1 Table). Furthermore, subjects with prior history of
202 malaria were also more likely to have been exposed to an alphavirus (aOR, 3.465; 95%
203 CI: 2.253-5.328) (S1 Table).

204 The prevalence of neutralizing antibodies against CHIKV and ONNV varied by
205 location in Senegal. The prevalence rates of CHIKV neutralizing antibodies were
206 42.86% (6/14) in Sindia, 66.67% (18/27) in Thies, and 14.47% (11/76) in Kedougou
207 (Fig. 1A). For ONNV, the neutralizing antibody prevalence rates of were 28.57% (4/14)
208 in Sindia, 14.81% (4/27) in Thies, and 50% (38/76) in Kedougou (Table 1, Fig. 1A).
209 Overall, 29.91% (35/117) had neutralizing antibodies against CHIKV, 39.32% (46/117)
210 had neutralizing antibodies against ONNV, 20.51% (24/117) were equivocal for both
211 CHIKV and ONNV, and 10.26% (12/117) were negative (Table 1). Moreover, of the
212 subjects with CHIKV neutralizing antibodies, 94.29% had cross-neutralizing antibodies
213 against ONNV (Fig. 1B-C). However, of the subjects with ONNV neutralizing antibodies,
214 only 53.33% had cross-neutralizing antibodies against CHIKV (Fig. 1B-C).



215
 216 **Fig. 1. Antibody neutralization against chikungunya (CHIKV) and o'nyong-nyong**
 217 **(ONNV) viruses in Senegal.** A) Map depicts locations in Senegal (Sindia, Thies, and
 218 Kedougou) where samples were collected from non-febrile subjects. For each location,
 219 donut charts represent number and corresponding percentages of subjects with
 220 neutralizing antibodies against CHIKV and ONNV or equivocal and negative results. B)
 221 CHIKV virus-like particle IgG-positive samples were tested for neutralizing antibodies
 222 against CHIKV and ONNV. Colors depict the 50% neutralizing antibody titers (NT50),
 223 each row represents one individual, and each column is the titer to CHIKV or ONNV. C)
 224 The percentage of NT50-confirmed CHIKV or ONNV subjects with cross-neutralizing
 225 antibodies to the heterologous virus.

226
 227
 228
 229
 230
 231

232 Multivariate logistic regression analyses revealed that subjects from Thies were
233 more likely to be infected with CHIKV (OR, 3.878; 95% CI: 0.783-19.205) (Table 2).
234 Conversely, being a resident of Kedougou (OR, 0.280; 95% CI: 0.074-1.054) and a prior
235 history of malaria parasite (aOR, 0.121; 95% CI: 0.049-0.300) infection were associated
236 with significantly lower odds of contracting CHIKV (Table 2). In contrast, subjects over
237 40 years of age were more likely to be infected with ONNV (OR, 7.896; 95% CI: 1.500-
238 41.556) (Table 3). Additionally, being a resident of Kedougou (OR, 3.180; 95% CI:
239 0.824-12.276) and malaria infection (aOR, 6.961; 95% CI: 2.456-19.732) were
240 associated with increased odds of contracting ONNV (Table 3).

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255 **Table 2. Risk factors for NT50-confirmed chikungunya virus (CHIKV) infections in**
 256 **Senegal**

CHIKV NT50-confirmed subjects						
Variable	Univariate		aOR		Multivariate	
	OR (95% CI)	p value	(95% CI)	p value	OR (95% CI)	p value
Age group						
≤ 20 years	Reference	0.255	Reference	0.268	Reference	0.688
21-40 years	1.07 (0.435- 2.635)		1.067 (0.433- 2.632)		1.571 (0.501- 4.930)	
> 40 years	2.529 (0.818- 7.826)		2.507 (0.802- 7.834)		1.471 (0.362- 5.978)	
Gender						
Male	Reference		Reference		Reference	
Female	1.167 (0.529- 2.572)	0.702	1.049 (0.467- 2.356)	0.907	1.022 (0.402- 2.597)	0.964
City						
Sindia	Reference	<0.001	Reference	<0.001	Reference	<0.001
Thies	3.167 (0.827- 12.126)		3.878 (0.783- 19.205)		3.878 (0.783- 19.205)	
Kedougou	0.237 (0.069- 0.815)		0.280 (0.074- 1.054)		0.280 (0.074- 1.054)	
Malaria status						
No	Reference					
Yes	0.114 (0.046- 0.278)	<0.001	0.121 (0.049- 0.300)	<0.001	–	–

257 OR- Odd ratio; aOR- adjusted odd ratio for sex and age

258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279

280 **Table 3. Risk factors for NT50-confirmed o’nyong-nyong virus (ONNV) infections**
 281 **in Senegal**

ONNV NT50-confirmed subjects						
Variable	Univariate			Multi-variate		
	OR (95% CI)	p value	aOR (95% CI)	p value	OR (95% CI)	p value
Age group						
≤ 20 years	Reference	0.081	Reference	0.075	Reference	0.022
21-40 years	2.396 (1.019-5.634)		2.423 (1.028-5.713)		2.356 (0.897-6.192)	
> 40 years	2.529 (0.818-7.826)		2.623 (0.837-8.224)		7.896 (1.500-41.556)	
Gender						
Male	Reference		Reference		Reference	
Female	0.882 (0.414-1.880)	0.746	0.835 (0.380-1.835)	0.653	0.872 (0.3730-2.038)	0.751
City						
Sindia	Reference	0.003	Reference	0.002	Reference	0.002
Thies	0.313 (0.059-1.658)		0.212 (0.026-1.752)		0.212 (0.026-1.752)	
Kedougou	2.569 (0.738-8.941)		3.180 (0.824-12.276)		3.180 (0.824-12.276)	
Malaria status						
No	Reference					
Yes	4.992 (1.962-12.703)	<0.001	6.961 (2.456-19.732)	<0.001	—	—

282 OR- Odd ratio; aOR- adjusted odd ratio for sex and age

283

284 Discussion

285 This study provides novel insights into the seroprevalence of CHIKV and
286 ONNV in Senegal, revealing significant regional differences that contribute to our
287 understanding of arboviral dynamics in West Africa. Our findings indicate a substantial
288 exposure to CHIKV and ONNV, with a detected anti-CHIKV IgG seroprevalence of
289 24.89% (117/470) among the study population (Table 1). This suggests an entrenched
290 alphavirus presence that might be influencing public health without sufficient recognition
291 or response.

292 The regional seroprevalences of anti-CHIKV IgG—14.89% in Sindia, 28.72%
293 in Thies, and 26.95% in Kedougou—reflect notable geographical variability, consistent
294 with previous studies across West Africa (Table 1). The significant variation between
295 these regions highlights the role of local environmental and ecological factors in
296 arbovirus transmission dynamics.

297 Our multivariate analysis underscores the influence of location, age, and malaria
298 status on the risk of CHIKV and ONNV infection. Residents of Thies showed a three-
299 fold increase in the likelihood of CHIKV infection compared to other regions, a finding
300 that could be attributed to specific local vector ecology or differences in human activities
301 that increase exposure to vectors (Table 2). Conversely, a history of malaria was
302 associated with a reduced likelihood of CHIKV exposure, suggesting possible cross-
303 immunity or behavioral adaptations that reduce exposure to vectors shared by both
304 pathogens (Table 2). For ONNV, older age and residence in Kedougou significantly
305 increased exposure risk, with Kedougou's unique environmental conditions potentially
306 facilitating higher mosquito density and virus transmission (Table 3).

307 Furthermore, the presence of neutralizing antibodies in our sample cohort—
308 29.91% for CHIKV and 39.32% for ONNV—underscores ongoing virus circulation and
309 potential for outbreaks (Fig. 1A). Notably, the high prevalence of ONNV neutralizing
310 antibodies in Kedougou (50%) compared to other regions points to specific regional
311 vulnerabilities, possibly driven by the overlapping mosquito vectors for malaria and
312 ONNV (Fig. 1A). We also found that a high percentage (94.29%) of subjects with CHIKV
313 neutralizing antibodies also had cross-neutralizing antibodies against ONNV (Fig. 1B-
314 C). Conversely, a smaller proportion (53.33%) of those with ONNV neutralizing
315 antibodies demonstrated cross-neutralization against CHIKV (Fig. 1B-C). These findings
316 corroborate a directional bias in immune cross-reactivity, where CHIKV exposure might
317 confer broader immunity, potentially impacting subsequent ONNV infection dynamics.

318 This asymmetric cross-reactivity could also be due to structural similarities in the
319 viral envelope proteins of CHIKV and ONNV, with CHIKV eliciting a broader neutralizing
320 response (33). This phenomenon is crucial for diagnostic tests, which may need
321 differentiation between past infections of these two viruses based on neutralizing
322 antibody profiles. Moreover, understanding the mechanisms behind this differential
323 cross-reactivity could guide vaccine strategies where a vaccine against one virus might
324 offer partial protection against the other, hence optimizing the control measures for both
325 viruses in regions where they co-circulate.

326 The higher prevalence observed in older age groups for CHIKV supports the
327 notion that cumulative exposure over time contributes to higher exposure rates. This
328 demographic insight is crucial for developing targeted public health strategies,
329 especially for vaccine deployment and vector control initiatives. The absence of a

330 similar age-related pattern for ONNV suggests different dynamics, potentially influenced
331 by sporadic outbreaks rather than continuous exposure.

332 Limitations of our study include the retrospective nature of sample collection,
333 which may not capture the most recent trends in virus circulation, and the absence of
334 entomological data to directly correlate vector abundance with seroprevalence rates.
335 Moreover, without concurrent clinical data, we cannot definitively link our serological
336 findings to symptomatic disease cases, potentially underestimating the true burden of
337 these infections. Also, IgG positivity does not necessarily reflect ongoing acute
338 infections but generally is a sign of previous exposure to the virus (resolved infection).
339 The insights into antibody cross-reactivity are essential for the interpretation of
340 seroprevalence data in regions endemic to both viruses, as they could lead to
341 overestimations of immunity against one virus due to past exposure to the other. This is
342 particularly relevant in vaccine efficacy trials and in the evaluation of natural immunity in
343 the population.

344 Conclusions drawn from our research illustrate the persistent circulation of
345 CHIKV and ONNV in Senegal, necessitating sustained surveillance and public health
346 preparedness to mitigate the impact of these and other arboviruses. The findings also
347 emphasize the importance of ecological and demographic factors in shaping the
348 epidemiology of these diseases, highlighting the need for comprehensive arbovirus
349 control strategies that integrate vector management with community health initiatives.
350 Future studies should aim to incorporate entomological and clinical data to provide a
351 more holistic understanding of the transmission dynamics and to facilitate the
352 development of targeted interventions, including vaccines and therapeutic measures.

353

354 **Acknowledgements**

355 We would like to thank Rutgers Global Health Institute, Rutgers Robert Wood Johnson
356 Medical School, and the Child Health Institute of New Jersey.

357

358 **Conflicts of Interest**

359 BBH is a co-founder of Mir Biosciences, Inc., a biotechnology company that develops
360 diagnostics and vaccines for infectious diseases, cancer, and autoimmunity.

361

362 **Author Contributions**

363 Conceptualization: BBH

364 Data curation: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,
365 MCS, ASB, BBH, DN

366 Formal analysis: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD,
367 KD, MCS, ASB, BBH, DN

368 Funding acquisition: BBH, DN

369 Investigation: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,
370 MCS, ASB, BBH, DN

371 Methodology: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,
372 MCS, ASB, BBH, DN

373 Project administration: BBH, DN

374 Resources: BBH, DN

375 Software: PBT, MS, BBH

376 Supervision: BBH, MS, DN

377 Validation: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,

378 MCS, ASB, BBH, DN

379 Visualization: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,

380 MCS, ASB, BBH, DN

381 Writing – original draft: PBT, BBH

382 Writing – review & editing: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY,

383 YD, BD, KD, MCS, ASB, BBH, DN

384

385 **References**

386 1. Pezzi L, LaBeaud AD, Reusken CB, Drexler JF, Vasilakis N, Diallo M, et al.

387 GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 2:

388 Epidemiological distribution of o'nyong-nyong virus. *Antiviral Res.* 2019;172:104611.

389 2. Zaid A, Burt FJ, Liu X, Poo YS, Zandi K, Suhrbier A, et al. Arthritogenic

390 alphaviruses: epidemiological and clinical perspective on emerging arboviruses. *Lancet*

391 *Infect Dis.* 2021;21(5):e123-e33.

392 3. Renault P, Balleydier E, D'Ortenzio E, Bavielle M, Filleul L. Epidemiology of

393 Chikungunya infection on Reunion Island, Mayotte, and neighboring countries. *Med Mal*

394 *Infect.* 2012;42(3):93-101.

395 4. Wahid B, Ali A, Rafique S, Idrees M. Global expansion of chikungunya virus:

396 mapping the 64-year history. *Int J Infect Dis.* 2017;58:69-76.

- 397 5. Zeller H, Van Bortel W, Sudre B. Chikungunya: Its History in Africa and Asia and
398 Its Spread to New Regions in 2013-2014. *J Infect Dis.* 2016;214(suppl 5):S436-S40.
- 399 6. Pezzi L, Diallo M, Rosa-Freitas MG, Vega-Rua A, Ng LFP, Boyer S, et al.
400 GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 5:
401 Entomological aspects. *Antiviral Res.* 2020;174:104670.
- 402 7. Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, et al.
403 Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya,
404 October 2004. *Am J Trop Med Hyg.* 2008;78(2):333-7.
- 405 8. Fischer M, Staples JE, Arboviral Diseases Branch NCfE, Zoonotic Infectious
406 Diseases CDC. Notes from the field: chikungunya virus spreads in the Americas -
407 Caribbean and South America, 2013-2014. *MMWR Morb Mortal Wkly Rep.*
408 2014;63(22):500-1.
- 409 9. Manzoor KN, Javed F, Ejaz M, Ali M, Mujaddadi N, Khan AA, et al. The global
410 emergence of Chikungunya infection: An integrated view. *Rev Med Virol.*
411 2022;32(3):e2287.
- 412 10. Teixeira MG, Andrade AM, Costa Mda C, Castro JN, Oliveira FL, Goes CS, et al.
413 East/Central/South African genotype chikungunya virus, Brazil, 2014. *Emerg Infect Dis.*
414 2015;21(5):906-7.
- 415 11. Corbet PS, Williams MC, Gillett JD. O'Nyong-Nyong fever: an epidemic virus
416 disease in East Africa. IV. Vector studies at epidemic sites. *Trans R Soc Trop Med Hyg.*
417 1961;55:463-80.

- 418 12. Williams MC, Woodall JP, Corbet PS, Gillett JD. O'nyong-Nyong Fever: An
419 Epidemic Virus Disease in East Africa. 8. Virus Isolations from Anopheles Mosquitoes.
420 Trans R Soc Trop Med Hyg. 1965;59:300-6.
- 421 13. Lanciotti RS, Ludwig ML, Rwaguma EB, Lutwama JJ, Kram TM, Karabatsos N,
422 et al. Emergence of epidemic O'nyong-nyong fever in Uganda after a 35-year absence:
423 genetic characterization of the virus. Virology. 1998;252(1):258-68.
- 424 14. Rezza G, Chen R, Weaver SC. O'nyong-nyong fever: a neglected mosquito-
425 borne viral disease. Pathog Glob Health. 2017;111(6):271-5.
- 426 15. Williams MC, Woodall JP, Gillett JD. O'nyong-Nyong Fever: An Epidemic Virus
427 Disease in East Africa. Vii. Virus Isolations from Man and Serological Studies up to
428 July 1961. Trans R Soc Trop Med Hyg. 1965;59:186-97.
- 429 16. Kiwanuka N, Sanders EJ, Rwaguma EB, Kawamata J, Ssengooba FP, Najjemba
430 R, et al. O'nyong-nyong fever in south-central Uganda, 1996-1997: clinical features and
431 validation of a clinical case definition for surveillance purposes. Clin Infect Dis.
432 1999;29(5):1243-50.
- 433 17. Tappe D, Kapaun A, Emmerich P, Campos Rde M, Cadar D, Gunther S, et al.
434 O'nyong-nyong virus infection imported to Europe from Kenya by a traveler. Emerg
435 Infect Dis. 2014;20(10):1766-7.
- 436 18. Johnson BK. O'nyong-nyong virus disease. Arboviruses: CRC Press; 2019. p.
437 217-24.
- 438 19. Kucharz EJ, Cebula-Byrska I. Chikungunya fever. Eur J Intern Med.
439 2012;23(4):325-9.

- 440 20. Schilte C, Staikovskiy F, Couderc T, Madec Y, Carpentier F, Kassab S, et al.
441 Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal
442 study. *PLoS neglected tropical diseases*. 2013;7(3):e2137.
- 443 21. Al-Emran HM, Eibach D, Krumkamp R, Ali M, Baker S, Biggs HM, et al. A
444 multicountry molecular analysis of *Salmonella enterica* serovar Typhi with reduced
445 susceptibility to ciprofloxacin in sub-Saharan Africa. *Clinical Infectious Diseases*.
446 2016;62(suppl_1):S42-S6.
- 447 22. Badiane AS, Ngom B, Ndiaye T, Cunningham D, Campbell J, Gaye A, et al.
448 Evidence of *Plasmodium vivax* circulation in western and eastern regions of Senegal:
449 implications for malaria control. *Malaria Journal*. 2024;23(1):149.
- 450 23. Diallo A, Sié A, Sirima S, Sylla K, Ndiaye M, Bountogo M, et al. An
451 epidemiological study to assess *Plasmodium falciparum* parasite prevalence and
452 malaria control measures in Burkina Faso and Senegal. *Malaria journal*. 2017;16:1-12.
- 453 24. Diallo M, Diongue K, Diagne G, Seck M, Ndiaye M, Dièye B, et al. *Plasmodium*
454 *ovale wallikeri* and *Plasmodium ovale curtisi* Malaria in Senegal in 2016. *Bulletin de la*
455 *Société de pathologie exotique*. 2017;110:286-90.
- 456 25. Dromigny J-A, Perrier-Gros-Claude J-D. Antimicrobial resistance of *Salmonella*
457 *enterica* serotype Typhi in Dakar, Senegal. *Clinical infectious diseases*. 2003;37(3):465-
458 6.
- 459 26. Harrois D, Breurec S, Seck A, Delauné A, Le Hello S, de La Gandara MP, et al.
460 Prevalence and characterization of extended-spectrum β -lactamase-producing clinical
461 *Salmonella enterica* isolates in Dakar, Senegal, from 1999 to 2009. *Clinical*
462 *Microbiology and Infection*. 2014;20(2):O109-O16.

- 463 27. Dieng I, Sadio BD, Gaye A, Sagne SN, Ndione MHD, Kane M, et al. Genomic
464 characterization of a reemerging Chikungunya outbreak in Kedougou, Southeastern
465 Senegal, 2023. *Emerg Microbes Infect.* 2024;13(1):2373308.
- 466 28. Pistone T, Ezzedine K, Boisvert M, Receveur MC, Schuffenecker I, Zeller H, et
467 al. Cluster of chikungunya virus infection in travelers returning from Senegal, 2006. *J*
468 *Travel Med.* 2009;16(4):286-8.
- 469 29. Roche S, Robin Y. [Human infections by Chikungunya virus in Rufisque
470 (Senegal), October-November, 1966]. *Bull Soc Med Afr Noire Lang Fr.* 1967;12(3):490-
471 6.
- 472 30. Saluzzo J, Cornet M, Digoutte J. Outbreak of a Chikungunya virus epidemic in
473 western Senegal in 1982. *Dakar medical.* 1983;28(3):497-500.
- 474 31. Sow A, Faye O, Diallo M, Diallo D, Chen R, Faye O, et al. Chikungunya Outbreak
475 in Kedougou, Southeastern Senegal in 2009-2010. *Open Forum Infect Dis.*
476 2018;5(1):ofx259.
- 477 32. LaBeaud AD, Banda T, Brichard J, Muchiri EM, Mungai PL, Mutuku FM, et al.
478 High rates of o'nyong nyong and Chikungunya virus transmission in coastal Kenya.
479 *PLoS Negl Trop Dis.* 2015;9(2):e0003436.
- 480 33. Hoze N, Diarra I, Sangare AK, Pastorino B, Pezzi L, Kouriba B, et al. Model-
481 based assessment of Chikungunya and O'nyong-nyong virus circulation in Mali in a
482 serological cross-reactivity context. *Nat Commun.* 2021;12(1):6735.

483

484 **Supporting information**

485 **S1 Table. Risk factors for alphavirus exposure (chikungunya virus virus-like**
486 **particle IgG+) in Senegal.** OR- Odd ratio; aOR- adjusted odd ratio for sex and age.